<!-- BPC-157 Research: 20 Studies, Chosen from 30, in Plain Language | https://bpc157pens.com/bpc-157-research/ -->

Guide · The literature

# Twenty studies, _in plain words._

**We read 30 peer-reviewed BPC-157 papers and kept the 20 that add something the others do not.** Each one below names the authors, shows the journal, and says what the study can and cannot support. Most of the animal work comes from one laboratory in Zagreb. The human evidence is three small reports.

By the bpc157pens.com Editorial Team · Last reviewed November 16, 2026 · 30 sources

## How we _chose._

Start with the two systematic reviews, then the three human reports, then the laboratory papers those reviews are built on. Skip a paper when a later one from the same authors already says it.

The search was PubMed, for papers with BPC-157, “BPC 157,” or “pentadecapeptide BPC” in the title. From that set we took 30 papers that are actually about this peptide, not a passing mention. A paper made the page when it was a systematic review, a human report, an experiment from a laboratory other than Zagreb, or the original Zagreb experiment that later papers cite. A paper was set aside when it repeated a review we already kept.

The journal plate on each study is drawn for this page. It names the real journal and year. It is not the publisher’s cover, and the authors did not write, review or endorse this site.

## What the reviews _conclude._

The careful reviews agree on the shape of the evidence: a large pile of animal papers, mostly from one group, and almost nothing controlled in people.

*Diagram: Journal plate for Acta Orthop. Belgica, 2026. Drawn for this page, not the publisher cover.*

01 · Systematic review · Humans

### What the human evidence amounts to

J. T. Poolton, J. Minett and A. Kazmi, 2026

Three human reports, 30 people, and no comparison group.

[1](#src-1) Poolton, Minett and Kazmi gathered the published human studies. They found three, with 30 people in all. None compared BPC-157 with a placebo or with usual care. They rated the certainty of that evidence as very low, and they wrote that it should not be used in people outside a regulated clinical trial. This paper reviews other papers. It is not a new experiment.

Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. _Acta Orthop Belg_. 2026;92(3). [PMID 42885452](https://pubmed.ncbi.nlm.nih.gov/42885452/) [doi:10.52628/92.3.15837](https://doi.org/10.52628/92.3.15837)

*Diagram: Journal plate for HSS Journal, 2025. Drawn for this page, not the publisher cover.*

02 · Systematic review · Orthopaedic sports medicine

### The animal literature, sorted

N. Vasireddi, H. Hahamyan, M. J. Salata and colleagues, 2025

Thirty-six studies, thirty-five of them preclinical.

[2](#src-2) Nikhil Vasireddi and colleagues reviewed BPC-157 research aimed at muscle, tendon, ligament and bone. Of 36 studies they judged relevant, 35 were preclinical (cells or animals) and one was clinical. A systematic review judges the papers that already exist. It does not show that the peptide works in people.

Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. _HSS J_. 2025;21(4):485–495. [PMID 40756949](https://pubmed.ncbi.nlm.nih.gov/40756949/) [doi:10.1177/15563316251355551](https://doi.org/10.1177/15563316251355551)

*Diagram: Journal plate for Cell and Tissue Research, 2019. Drawn for this page, not the publisher cover.*

03 · Critical review · Outside the original lab

### An outside reading of the soft-tissue papers

Daniel Gwyer, Nicholas M. Wragg and Samantha L. Wilson, 2019

Most of the musculoskeletal experiments come from one laboratory.

[3](#src-3) Gwyer, Wragg and Wilson reviewed the tendon, ligament and muscle papers from outside the Zagreb group that produced most of them. They describe reported effects in animals, and they underline the limits: one dominant laboratory, and a peptide that is difficult to keep intact in the body. This is a critique of the literature, not a new experiment.

Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. _Cell Tissue Res_. 2019;377(2):153–159. [PMID 30915550](https://pubmed.ncbi.nlm.nih.gov/30915550/) [doi:10.1007/s00441-019-03016-8](https://doi.org/10.1007/s00441-019-03016-8)

*Diagram: Journal plate for Pharmaceuticals, 2025. Drawn for this page, not the publisher cover.*

04 · Literature and patent review · Poland

### The papers and the patents

Michalina Józwiak, Marta Bauer, Wojciech Kamysz and Patrycja Kleczkowska, 2025

A survey of published claims, written by people who did not do the original experiments.

[4](#src-4) Józwiak, Bauer, Kamysz and Kleczkowska read the scientific papers and the patents. They describe many reported effects in animal models and few reported side effects. A review can only be as strong as the studies underneath it, and those studies are mostly rat experiments from one group. The authors also discuss anti-doping rules. For the rule in force today, this site relies on the WADA Prohibited List, which lists BPC-157 under S0.

Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and possible medical application of the BPC 157 peptide—literature and patent review. _Pharmaceuticals (Basel)_. 2025;18(2):185. [PMID 40005999](https://pubmed.ncbi.nlm.nih.gov/40005999/) [doi:10.3390/ph18020185](https://doi.org/10.3390/ph18020185)

*Diagram: Journal plate for Frontiers in Pharmacology, 2021. Drawn for this page, not the publisher cover.*

05 · Review · The Zagreb group on its own work

### Their account of wound models

Sven Seiwerth, Predrag Sikirić and colleagues, 2021

A review by the laboratory that ran most of the experiments.

[5](#src-5) Seiwerth, Sikirić and their colleagues summarize their own animal work on skin wounds, burns and ulcers. Because the reviewers are also the experimenters, the paper is the group’s account of its research, not an independent check. Treat the reported effects as claims from that body of rat studies.

Seiwerth S, Milavic M, Vukojevic J, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. _Front Pharmacol_. 2021;12:627533. [PMID 34267654](https://pubmed.ncbi.nlm.nih.gov/34267654/) [doi:10.3389/fphar.2021.627533](https://doi.org/10.3389/fphar.2021.627533)

*Diagram: Journal plate for Gut and Liver, 2020. Drawn for this page, not the publisher cover.*

06 · Review · Cytoprotection

### The idea behind the peptide

Predrag Sikirić, Ki-Baik Hahm and colleagues, 2020

Stomach protection, extended by the authors to other organs.

[6](#src-6) Sikirić, with Ki-Baik Hahm and the Zagreb group, argue that BPC-157 fits an older idea called cytoprotection: keeping a tissue lining intact after an insult, first in the stomach and then, they propose, elsewhere. The paper is their reading of decades of their own studies. Hahm is a coauthor from outside that core group. It is an argument, not a human trial.

Sikirić P, Hahm KB, Blagaic AB, et al. Stable gastric pentadecapeptide BPC 157, Robert’s stomach cytoprotection/adaptive cytoprotection/organoprotection, and Selye’s stress coping response. _Gut Liver_. 2020;14(2):153–167. [PMID 31158953](https://pubmed.ncbi.nlm.nih.gov/31158953/) [doi:10.5009/gnl18490](https://doi.org/10.5009/gnl18490)

## The three human _reports._

These are the human studies Poolton and colleagues counted. Together they describe 30 people. None has a comparison group.

*Diagram: Journal plate for Altern. Ther. Health Med., 2021. Drawn for this page, not the publisher cover.*

07 · Human report · No comparison group

### A look back at knee charts

E. Lee and B. Padgett, 2021

Sixteen people’s charts. No untreated group.

[7](#src-7) Lee and Padgett looked back at the charts of 16 people who had been given BPC-157 for knee pain. There was no comparison group, so a change in a chart cannot be attributed to the peptide. Poolton and colleagues later rated this report poor quality. It is one of the three human papers in that review. This site does not describe a dose or a procedure.

Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. _Altern Ther Health Med_. 2021;27(4):8–13. [PMID 34324435](https://pubmed.ncbi.nlm.nih.gov/34324435/)

*Diagram: Journal plate for Altern. Ther. Health Med., 2024. Drawn for this page, not the publisher cover.*

08 · Human pilot · 12 people

### A pilot in interstitial cystitis

E. Lee, C. Walker and B. Ayadi, 2024

Twelve people, and no comparison group.

[8](#src-8) Lee, Walker and Ayadi reported on 12 people with interstitial cystitis who received BPC-157. A pilot this small, without a comparison group, cannot show that a treatment works. The 2026 systematic review grouped it with the other human reports and judged the set poor quality. No dose is repeated here.

Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. _Altern Ther Health Med_. 2024;30(10):12–17. [PMID 39325560](https://pubmed.ncbi.nlm.nih.gov/39325560/)

*Diagram: Journal plate for Altern. Ther. Health Med., 2025. Drawn for this page, not the publisher cover.*

09 · Human pilot · Two people

### Two people, watched for a short time

E. Lee and K. Burgess, 2025

A safety pilot, not a demonstration that the peptide is safe.

[9](#src-9) Lee and Burgess describe giving BPC-157 by vein to two people and watching for short-term problems. Two people, no comparison group, and a short window cannot establish safety. Reviewers have found no controlled safety data in people. This page does not repeat the amount they gave.

Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. _Altern Ther Health Med_. 2025;31(5):20–24. [PMID 40131143](https://pubmed.ncbi.nlm.nih.gov/40131143/)

## Cells, vessels, and _animal models._

Outside Zagreb, the clearest laboratory papers are two tendon-cell studies from Taiwan, a blood-vessel study, and a pharmacokinetics study in rats and dogs. The injury models underneath the reviews are the Zagreb rat papers.

*Diagram: Journal plate for Frontiers in Pharmacology, 2022. Drawn for this page, not the publisher cover.*

10 · Laboratory · Rats and dogs

### How quickly it leaves the blood

L. He, D. Feng, H. Guo, Y. Zhou and colleagues, 2022

Measured in animals. Gone from the bloodstream in under 30 minutes.

[10](#src-10) He and colleagues tracked BPC-157 through rats and beagle dogs: where it went, how it was broken down, and how fast it left. They reported an elimination half-life under 30 minutes. This is a pharmacokinetics study, not a human trial. The paper’s title calls the peptide a potential wound drug. That is the authors’ wording. BPC-157 is not an approved drug.

He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. _Front Pharmacol_. 2022;13:1026182. [PMID 36588717](https://pubmed.ncbi.nlm.nih.gov/36588717/) [doi:10.3389/fphar.2022.1026182](https://doi.org/10.3389/fphar.2022.1026182)

*Diagram: Journal plate for J Mol Med, 2017. Drawn for this page, not the publisher cover.*

11 · Laboratory · Vessels

### More blood vessels, in three lab models

M. J. Hsieh and colleagues, 2017

A chick-embryo membrane, human vessel cells, and rats.

[11](#src-11) Hsieh and colleagues reported more new blood vessels in a chick-embryo membrane, in human cells that line vessels, and in rats. They tied that to a receptor called VEGFR2. New vessels are part of ordinary repair. The same finding is why some reviewers worry, in theory, about tumor growth. This study did not test that worry, and it is not a clinical trial.

Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. _J Mol Med (Berl)_. 2017;95(3):323–333. [PMID 27847966](https://pubmed.ncbi.nlm.nih.gov/27847966/) [doi:10.1007/s00109-016-1488-y](https://doi.org/10.1007/s00109-016-1488-y)

*Diagram: Journal plate for Molecules, 2014. Drawn for this page, not the publisher cover.*

12 · Cells in a dish · Rat tendon

### A receptor signal goes up

C. H. Chang, W. C. Tsai, Y. H. Hsu and J. H. S. Pang, 2014

Tendon cells from rats, not a study in people.

[12](#src-12) Chang, Tsai, Hsu and Pang grew tendon cells from rats and reported that BPC-157 increased the cells’ growth-hormone receptor. The work was done in a dish, in one laboratory. Nothing in the paper was measured in a person.

Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. _Molecules_. 2014;19(11):19066–19077. [PMID 25415472](https://pubmed.ncbi.nlm.nih.gov/25415472/) [doi:10.3390/molecules191119066](https://doi.org/10.3390/molecules191119066)

*Diagram: Journal plate for J Appl Physiol, 2011. Drawn for this page, not the publisher cover.*

13 · Cells in a dish · Rat tendon

### Tendon cells spread and move

C. H. Chang, W. C. Tsai, M. S. Lin, Y. H. Hsu and J. H. S. Pang, 2011

A cell-adhesion pathway called FAK–paxillin.

[13](#src-13) The same Taiwan laboratory reported that rat tendon cells exposed to BPC-157 spread, survived and migrated more. They linked that behavior to FAK–paxillin, a pathway cells use to grip a surface and move. It is a dish experiment. It does not show repair of a tendon in a person.

Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. _J Appl Physiol_. 2011;110(3):774–780. [PMID 21030672](https://pubmed.ncbi.nlm.nih.gov/21030672/) [doi:10.1152/japplphysiol.00945.2010](https://doi.org/10.1152/japplphysiol.00945.2010)

*Diagram: Journal plate for Biomedicines, 2021. Drawn for this page, not the publisher cover.*

14 · Rat experiment · Muscle and tendon

### A tendon pulled off its muscle

M. Japjec and colleagues, 2021

A junction the authors say does not close on its own in this model.

[14](#src-14) Japjec and colleagues separated the quadriceps tendon from the quadriceps muscle in rats. They reported better structure and strength when BPC-157 was given, judged by appearance, microscopy and mechanical testing. It is one laboratory’s rat model. This page does not repeat the dose.

Japjec M, Horvat Pavlov K, Petrovic A, et al. Stable gastric pentadecapeptide BPC 157 as a therapy for the disable myotendinous junctions in rats. _Biomedicines_. 2021;9(11):1547. [PMID 34829776](https://pubmed.ncbi.nlm.nih.gov/34829776/) [doi:10.3390/biomedicines9111547](https://doi.org/10.3390/biomedicines9111547)

*Diagram: Journal plate for J Orthop Res, 2010. Drawn for this page, not the publisher cover.*

15 · Rat experiment · Ligament

### A cut knee ligament

T. Cerovecki and colleagues, including Seiwerth and Sikirić, 2010

Reported ligament repair in rats, with the peptide given alone.

[15](#src-15) Cerovecki, Bojanic, Seiwerth, Sikirić and colleagues cut a knee ligament in rats and reported better healing when BPC-157 was given on its own, without a carrier cream or scaffold. Rats only, and the same Zagreb laboratory as most of the injury papers. Not a human study.

Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. _J Orthop Res_. 2010;28(9):1155–1161. [PMID 20225319](https://pubmed.ncbi.nlm.nih.gov/20225319/) [doi:10.1002/jor.21107](https://doi.org/10.1002/jor.21107)

*Diagram: Journal plate for Surgery Today, 2008. Drawn for this page, not the publisher cover.*

16 · Rat experiment · Muscle

### A crushed muscle

T. Novinscak and colleagues, 2008

Faster recovery, reported in one crush model.

[16](#src-16) Novinscak and colleagues crushed a muscle in rats and reported faster structural and functional recovery with BPC-157. The work is from the Zagreb group. A single animal model does not establish an effect in any other species, including people.

Novinscak T, Brcic L, Staresinic M, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. _Surg Today_. 2008;38(8):716–725. [PMID 18668315](https://pubmed.ncbi.nlm.nih.gov/18668315/) [doi:10.1007/s00595-007-3706-2](https://doi.org/10.1007/s00595-007-3706-2)

*Diagram: Journal plate for Surgery Today, 2007. Drawn for this page, not the publisher cover.*

17 · Rat experiment · Intestine

### A rejoined piece of intestine

T. Vuksic and colleagues, 2007

The rat finding is the surgical join. The human-trial claim is not a published trial.

[17](#src-17) Vuksic and colleagues cut and rejoined the small intestine in rats and reported that the join held more often when BPC-157 was given. The title mentions human inflammatory-bowel-disease trials run under the names PL-10, PLD-116 and PL 14736. Those results are not published here as a full controlled study, so this page treats the rat operation as the finding and does not treat the trial claim as established.

Vuksic T, Zoricic I, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat. _Surg Today_. 2007;37(9):768–777. [PMID 17713731](https://pubmed.ncbi.nlm.nih.gov/17713731/) [doi:10.1007/s00595-006-3498-9](https://doi.org/10.1007/s00595-006-3498-9)

*Diagram: Journal plate for J Orthop Res, 2006. Drawn for this page, not the publisher cover.*

18 · Rat experiment · Tendon to bone

### Tendon pulled off the heel bone

Andrija Krivic, Tomislav Anić, Sven Seiwerth, Dubravko Huljev and Predrag Sikirić, 2006

Reattachment, including when a corticosteroid was also given.

[18](#src-18) Krivic, Anić, Seiwerth, Huljev and Sikirić detached the Achilles tendon from the heel bone in rats. They reported that it reattached, including in animals also given a corticosteroid, which on its own tends to weaken that kind of repair. Rats only, one laboratory. No dose is repeated here.

Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. _J Orthop Res_. 2006;24(5):982–989. [PMID 16583442](https://pubmed.ncbi.nlm.nih.gov/16583442/) [doi:10.1002/jor.20096](https://doi.org/10.1002/jor.20096)

*Diagram: Journal plate for J Orthop Res, 2003. Drawn for this page, not the publisher cover.*

19 · Rat experiment · Achilles tendon

### The tendon paper later studies cite

M. Staresinic and colleagues, 2003

A cut Achilles tendon in rats, plus tendon cells in a dish.

[19](#src-19) Staresinic and colleagues cut the Achilles tendon in rats and also grew tendon cells in culture. They reported faster tendon repair and faster cell growth. Later tendon papers, including the Chang studies above, cite this one. It remains a rat study from the Zagreb group.

Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. _J Orthop Res_. 2003;21(6):976–983. [PMID 14554208](https://pubmed.ncbi.nlm.nih.gov/14554208/) [doi:10.1016/S0736-0266(03)00110-4](https://doi.org/10.1016/S0736-0266\(03\)00110-4)

*Diagram: Journal plate for J Physiol Paris, 1997. Drawn for this page, not the publisher cover.*

20 · Early laboratory report

### Where the healing claims started

Sven Seiwerth and Predrag Sikirić, 1997

A wide early survey, not a human trial.

[20](#src-20) Seiwerth and Sikirić, with their colleagues, reported effects of the 15-amino-acid peptide on several pieces of experimental healing. It is an early, broad laboratory paper. The later Zagreb injury studies grew out of this line of work. It is not evidence about people.

Seiwerth S, Sikiric P, Grabarevic Z, et al. BPC 157’s effect on healing. _J Physiol Paris_. 1997;91(3–5):173–178. [PMID 9403790](https://pubmed.ncbi.nlm.nih.gov/9403790/) [doi:10.1016/s0928-4257(97)89480-6](https://doi.org/10.1016/s0928-4257\(97\)89480-6)

## Ten we read and _set aside._

These ten are real papers. Each one repeats a review we kept, or it is narrower than the experiment we featured in its place.

21.  Sikiric P, Seiwerth S, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. _Inflammopharmacology_. 2006;14(5–6):214–221. [PMID 17186181](https://pubmed.ncbi.nlm.nih.gov/17186181/) [doi:10.1007/s10787-006-1531-7](https://doi.org/10.1007/s10787-006-1531-7)
     
     Set aside. Same group’s essay on its trial program. The later Gut and Liver review covers the argument, and the human-trial results are not published as a paper we could assess.
     
22.  Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. _J Physiol Pharmacol_. 2009;60(Suppl 7):191–196. [PMID 20388964](https://pubmed.ncbi.nlm.nih.gov/20388964/)
     
     Set aside. A short angiogenesis note from Zagreb. Hsieh 2017 is the fuller vessel paper, and it comes from another laboratory.
     
23.  Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. _Curr Pharm Des_. 2011;17(16):1612–1632. [PMID 21548867](https://pubmed.ncbi.nlm.nih.gov/21548867/) [doi:10.2174/138161211796196954](https://doi.org/10.2174/138161211796196954)
     
     Set aside. A gastrointestinal review from the same group, largely restated in the 2020 Gut and Liver paper we kept.
     
24.  Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. _Curr Neuropharmacol_. 2016;14(8):857–865. [PMID 27138887](https://pubmed.ncbi.nlm.nih.gov/27138887/) [doi:10.2174/1570159x13666160502153022](https://doi.org/10.2174/1570159x13666160502153022)
     
     Set aside. A theoretical review of the brain-gut idea. No new experiment, and the same laboratory.
     
25.  Sikiric P, Seiwerth S, Rucman R, et al. Stress in gastrointestinal tract and stable gastric pentadecapeptide BPC 157. _Curr Pharm Des_. 2017;23(27):4012–4028. [PMID 28228068](https://pubmed.ncbi.nlm.nih.gov/28228068/) [doi:10.2174/1381612823666170220163219](https://doi.org/10.2174/1381612823666170220163219)
     
     Set aside. Another Zagreb review, this one framed around stress. It does not add a finding the 2020 paper does not already argue.
     
26.  Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and standard angiogenic growth factors. _Curr Pharm Des_. 2018;24(18):1972–1989. [PMID 29998800](https://pubmed.ncbi.nlm.nih.gov/29998800/) [doi:10.2174/1381612824666180712110447](https://doi.org/10.2174/1381612824666180712110447)
     
     Set aside. A growth-factor review that covers the same ground as the 2021 wound-healing review.
     
27.  Wu H, Wei M, Li N, et al. Clopidogrel-induced gastric injury in rats is attenuated by stable gastric pentadecapeptide BPC 157. _Drug Des Devel Ther_. 2020;14:5599–5610. [PMID 33376304](https://pubmed.ncbi.nlm.nih.gov/33376304/) [doi:10.2147/DDDT.S284163](https://doi.org/10.2147/DDDT.S284163)
     
     Set aside. A real independent experiment, from Nanjing, in one rat model of stomach injury. Narrower than the papers we kept, so it is listed rather than featured.
     
28.  Bilic Z, Gojkovic S, Kalogjera L, et al. Complex therapeutic effect of cytoprotective pentadecapeptide BPC 157 in rats with perforated stomach. _J Physiol Pharmacol_. 2021;72(6). [PMID 35485358](https://pubmed.ncbi.nlm.nih.gov/35485358/) [doi:10.26402/jpp.2021.6.11](https://doi.org/10.26402/jpp.2021.6.11)
     
     Set aside. One very specific Zagreb rat model, a surgically perforated stomach. It does not change the picture drawn by the broader papers.
     
29.  Staresinic M, Japjec M, Vranes H, et al. Stable gastric pentadecapeptide BPC 157 and striated, smooth, and heart muscle. _Biomedicines_. 2022;10(12):3221. [PMID 36551977](https://pubmed.ncbi.nlm.nih.gov/36551977/) [doi:10.3390/biomedicines10123221](https://doi.org/10.3390/biomedicines10123221)
     
     Set aside. A muscle review that retells Japjec 2021 and earlier Zagreb experiments. We kept the experiment instead of the retelling.
     
30.  McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. _Curr Rev Musculoskelet Med_. 2025;18(12):611–619. [PMID 40789979](https://pubmed.ncbi.nlm.nih.gov/40789979/) [doi:10.1007/s12178-025-09990-7](https://doi.org/10.1007/s12178-025-09990-7)
     
     Set aside. A narrative review that reaches the same caution as Vasireddi and Poolton. Those two used a systematic method, so they are the ones on the page.
     

## Sources

Study authors are credited for their published research. None of them wrote, reviewed or endorsed this site. Citations 1–20 are the studies on this page. Citations 21–30 are the papers we read and set aside.

1.  Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. _Acta Orthop Belg_. 2026;92(3). [PMID 42885452](https://pubmed.ncbi.nlm.nih.gov/42885452/) [doi:10.52628/92.3.15837](https://doi.org/10.52628/92.3.15837)
2.  Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. _HSS J_. 2025;21(4):485–495. [PMID 40756949](https://pubmed.ncbi.nlm.nih.gov/40756949/) [doi:10.1177/15563316251355551](https://doi.org/10.1177/15563316251355551)
3.  Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. _Cell Tissue Res_. 2019;377(2):153–159. [PMID 30915550](https://pubmed.ncbi.nlm.nih.gov/30915550/) [doi:10.1007/s00441-019-03016-8](https://doi.org/10.1007/s00441-019-03016-8)
4.  Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and possible medical application of the BPC 157 peptide—literature and patent review. _Pharmaceuticals (Basel)_. 2025;18(2):185. [PMID 40005999](https://pubmed.ncbi.nlm.nih.gov/40005999/) [doi:10.3390/ph18020185](https://doi.org/10.3390/ph18020185)
5.  Seiwerth S, Milavic M, Vukojevic J, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. _Front Pharmacol_. 2021;12:627533. [PMID 34267654](https://pubmed.ncbi.nlm.nih.gov/34267654/) [doi:10.3389/fphar.2021.627533](https://doi.org/10.3389/fphar.2021.627533)
6.  Sikirić P, Hahm KB, Blagaic AB, et al. Stable gastric pentadecapeptide BPC 157, Robert’s stomach cytoprotection/adaptive cytoprotection/organoprotection, and Selye’s stress coping response. _Gut Liver_. 2020;14(2):153–167. [PMID 31158953](https://pubmed.ncbi.nlm.nih.gov/31158953/) [doi:10.5009/gnl18490](https://doi.org/10.5009/gnl18490)
7.  Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. _Altern Ther Health Med_. 2021;27(4):8–13. [PMID 34324435](https://pubmed.ncbi.nlm.nih.gov/34324435/)
8.  Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. _Altern Ther Health Med_. 2024;30(10):12–17. [PMID 39325560](https://pubmed.ncbi.nlm.nih.gov/39325560/)
9.  Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. _Altern Ther Health Med_. 2025;31(5):20–24. [PMID 40131143](https://pubmed.ncbi.nlm.nih.gov/40131143/)
10.  He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. _Front Pharmacol_. 2022;13:1026182. [PMID 36588717](https://pubmed.ncbi.nlm.nih.gov/36588717/) [doi:10.3389/fphar.2022.1026182](https://doi.org/10.3389/fphar.2022.1026182)
11.  Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. _J Mol Med (Berl)_. 2017;95(3):323–333. [PMID 27847966](https://pubmed.ncbi.nlm.nih.gov/27847966/) [doi:10.1007/s00109-016-1488-y](https://doi.org/10.1007/s00109-016-1488-y)
12.  Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. _Molecules_. 2014;19(11):19066–19077. [PMID 25415472](https://pubmed.ncbi.nlm.nih.gov/25415472/) [doi:10.3390/molecules191119066](https://doi.org/10.3390/molecules191119066)
13.  Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. _J Appl Physiol_. 2011;110(3):774–780. [PMID 21030672](https://pubmed.ncbi.nlm.nih.gov/21030672/) [doi:10.1152/japplphysiol.00945.2010](https://doi.org/10.1152/japplphysiol.00945.2010)
14.  Japjec M, Horvat Pavlov K, Petrovic A, et al. Stable gastric pentadecapeptide BPC 157 as a therapy for the disable myotendinous junctions in rats. _Biomedicines_. 2021;9(11):1547. [PMID 34829776](https://pubmed.ncbi.nlm.nih.gov/34829776/) [doi:10.3390/biomedicines9111547](https://doi.org/10.3390/biomedicines9111547)
15.  Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. _J Orthop Res_. 2010;28(9):1155–1161. [PMID 20225319](https://pubmed.ncbi.nlm.nih.gov/20225319/) [doi:10.1002/jor.21107](https://doi.org/10.1002/jor.21107)
16.  Novinscak T, Brcic L, Staresinic M, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat. _Surg Today_. 2008;38(8):716–725. [PMID 18668315](https://pubmed.ncbi.nlm.nih.gov/18668315/) [doi:10.1007/s00595-007-3706-2](https://doi.org/10.1007/s00595-007-3706-2)
17.  Vuksic T, Zoricic I, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat. _Surg Today_. 2007;37(9):768–777. [PMID 17713731](https://pubmed.ncbi.nlm.nih.gov/17713731/) [doi:10.1007/s00595-006-3498-9](https://doi.org/10.1007/s00595-006-3498-9)
18.  Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. _J Orthop Res_. 2006;24(5):982–989. [PMID 16583442](https://pubmed.ncbi.nlm.nih.gov/16583442/) [doi:10.1002/jor.20096](https://doi.org/10.1002/jor.20096)
19.  Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. _J Orthop Res_. 2003;21(6):976–983. [PMID 14554208](https://pubmed.ncbi.nlm.nih.gov/14554208/) [doi:10.1016/S0736-0266(03)00110-4](https://doi.org/10.1016/S0736-0266\(03\)00110-4)
20.  Seiwerth S, Sikiric P, Grabarevic Z, et al. BPC 157’s effect on healing. _J Physiol Paris_. 1997;91(3–5):173–178. [PMID 9403790](https://pubmed.ncbi.nlm.nih.gov/9403790/) [doi:10.1016/s0928-4257(97)89480-6](https://doi.org/10.1016/s0928-4257\(97\)89480-6)
21.  Sikiric P, Seiwerth S, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. _Inflammopharmacology_. 2006;14(5–6):214–221. [PMID 17186181](https://pubmed.ncbi.nlm.nih.gov/17186181/) [doi:10.1007/s10787-006-1531-7](https://doi.org/10.1007/s10787-006-1531-7)
22.  Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. _J Physiol Pharmacol_. 2009;60(Suppl 7):191–196. [PMID 20388964](https://pubmed.ncbi.nlm.nih.gov/20388964/)
23.  Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. _Curr Pharm Des_. 2011;17(16):1612–1632. [PMID 21548867](https://pubmed.ncbi.nlm.nih.gov/21548867/) [doi:10.2174/138161211796196954](https://doi.org/10.2174/138161211796196954)
24.  Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. _Curr Neuropharmacol_. 2016;14(8):857–865. [PMID 27138887](https://pubmed.ncbi.nlm.nih.gov/27138887/) [doi:10.2174/1570159x13666160502153022](https://doi.org/10.2174/1570159x13666160502153022)
25.  Sikiric P, Seiwerth S, Rucman R, et al. Stress in gastrointestinal tract and stable gastric pentadecapeptide BPC 157. _Curr Pharm Des_. 2017;23(27):4012–4028. [PMID 28228068](https://pubmed.ncbi.nlm.nih.gov/28228068/) [doi:10.2174/1381612823666170220163219](https://doi.org/10.2174/1381612823666170220163219)
26.  Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and standard angiogenic growth factors. _Curr Pharm Des_. 2018;24(18):1972–1989. [PMID 29998800](https://pubmed.ncbi.nlm.nih.gov/29998800/) [doi:10.2174/1381612824666180712110447](https://doi.org/10.2174/1381612824666180712110447)
27.  Wu H, Wei M, Li N, et al. Clopidogrel-induced gastric injury in rats is attenuated by stable gastric pentadecapeptide BPC 157. _Drug Des Devel Ther_. 2020;14:5599–5610. [PMID 33376304](https://pubmed.ncbi.nlm.nih.gov/33376304/) [doi:10.2147/DDDT.S284163](https://doi.org/10.2147/DDDT.S284163)
28.  Bilic Z, Gojkovic S, Kalogjera L, et al. Complex therapeutic effect of cytoprotective pentadecapeptide BPC 157 in rats with perforated stomach. _J Physiol Pharmacol_. 2021;72(6). [PMID 35485358](https://pubmed.ncbi.nlm.nih.gov/35485358/) [doi:10.26402/jpp.2021.6.11](https://doi.org/10.26402/jpp.2021.6.11)
29.  Staresinic M, Japjec M, Vranes H, et al. Stable gastric pentadecapeptide BPC 157 and striated, smooth, and heart muscle. _Biomedicines_. 2022;10(12):3221. [PMID 36551977](https://pubmed.ncbi.nlm.nih.gov/36551977/) [doi:10.3390/biomedicines10123221](https://doi.org/10.3390/biomedicines10123221)
30.  McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. _Curr Rev Musculoskelet Med_. 2025;18(12):611–619. [PMID 40789979](https://pubmed.ncbi.nlm.nih.gov/40789979/) [doi:10.1007/s12178-025-09990-7](https://doi.org/10.1007/s12178-025-09990-7)
